CytomX Therapeutics
CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company based in South San Francisco, California, specializing in the development of innovative antibody therapeutics utilizing its proprietary Probody technology platform. This approach enables the creation of proteolytically-activated antibodies designed to improve targeting of cancer cells while minimizing toxicity to healthy tissues. The company’s clinical-stage product candidates include CX-072, targeting programmed cell death ligand 1; CX-2009, a drug conjugate aimed at CD166; BMS-986249, for treating metastatic melanoma; CX-2029, which targets CD71 in solid tumors; and BMS-986288, an anti-CTLA-4 therapeutic. CytomX has established strategic collaborations with several leading pharmaceutical companies, including AbbVie, Amgen, and Bristol-Myers Squibb, to further the development of its Probody therapeutics. Founded in 2008, CytomX Therapeutics aims to provide patients with more effective and less toxic treatment options for cancer and other severe illnesses.
Ardais Corporation is a clinical genomics company, is dedicated to enhancing and accelerating biomedical research by introducing actual human disease into the pharmaceutical discovery research process. To achieve its goals, Ardais has incorporated multi-disciplinary scientific expertise into its operations, including pathology, molecular biology and genomics, statistical genomics, bioinformatics and medical informatics, as well as process management skills such as logistics, industrial engineering, and robotics. The result of this unique integration is a state-of-the-art, proprietary discovery platform that is dramatically transforming genomic research and leading the way to novel diagnostic and therapeutic solutions.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.